Late-breaking data demonstrate improved progression-free survival in patients with metastatic colorectal cancer after treatment with boston scientific therasphere™ y-90 glass microspheres

Marlborough, mass., sept. 20, 2021 /prnewswire/ -- boston scientific corporation (nyse: bsx) announced the epoch clinical trial of the therasphere™ y-90 glass microspheres (therasphere treatment) successfully met both primary endpoints, including progression-free survival (pfs) and hepatic progression-free survival (hpfs) of patients with metastatic colorectal cancer (mcrc) of the liver.
BSX Ratings Summary
BSX Quant Ranking